Description
Fibrovein solution for injection
Fibrovein is a detergent based sclerosant and is licensed for the treatment of varicose veins. It is a sterile aqueous injection of Sodium Tetradecyl Sulfate (STS), an anionic detergent. It has been used in the treatment of varicose veins since 1946. Fibrovein is manufactured under cGMP conditions and complies with
Show More
Fibrovein solution for injection
Fibrovein is a detergent based sclerosant and is licensed for the treatment of varicose veins. It is a sterile aqueous injection of Sodium Tetradecyl Sulfate (STS), an anionic detergent. It has been used in the treatment of varicose veins since 1946. Fibrovein is manufactured under cGMP conditions and complies with all EU regulations. The product was first registered in the UK in 1967 when it was marketed under the name of STD injection. It is currently registered in over 20 countries including UK, France, Spain, Czech Republic, Portugal, Ireland, Australia, New Zealand and South Africa.
Fibrovein is manufactured in the UK and is the only STS based sclerosing solution that complies with British Pharmacopoeia specifications. Sclerotherapy is a medical procedure used to eliminate varicose veins and spider veins.
How Does Fibrovein Work?
Fibrovein occludes veins by the process of sclerosis. The aim of sclerosis is to produce maximum endothelial damage with subsequent minimal thrombus formation leading to fibrosis of the treated vein.
The inner layer of a vein is a layer of cells called the endothelium. It is this layer that prevents blood clotting in the veins the aim of sclerosis is to damage this layer.
Endothelial damage
When injected into a vein Fibrovein displaces the blood and damages the endothelium by destroying the cell membrane.
Destruction of the endothelial cells results in the exposure of sub-endothelial collagen fibres in the vein wall.
Reaction of the vein
As a response to the damage the vein usually goes into spasm and the clotting cascade is initiated with release of platelet factors.
Vein occlusion
Essentially the damage caused by Fibrovein initiates the body’s wound healing response and as soon as fresh blood passes through the sclerosed vein it clots and sticks to the damaged vein wall.
The blood forms a hard ‘sclerothrombus’ firmly attached to the vein wall. The hard sclerothrombus occludes the vein. Fibroblasts infiltrate the thrombus and begin laying down collagen fibre, reorganising the thrombus into scar tissue.
he body’s healing mechanism converts the sclerothrombus and vein into a fibrous cord, resulting in complete obliteration of the vein
Fibrovein is licensed for the treatment of uncomplicated primary varicose veins, recurrent or residual varicose veins following surgery, reticular veins, venules and spider veins of the lower extremities that show simple dilation.
The sclerosant should be administered intravenously in small aliquots at multiple sites along the vein to be treated either as a liquid or as a sclerosant/air mixture (foam), for the treatment of larger veins with the 1% and 3% solutions. The objective is to achieve optimal destruction of the vessel wall with the minimum concentration of sclerosant necessary for a clinical result. If the concentration is too high necrosis or other adverse sequelae may occur.
The recommended diluent is sterile water (water for injection). Normal Saline (sterile) is satisfactory but not necessary.
Less